Irish Medicines Board safety warnings: do they affect prescribing rates in primary care? - Wikidata - awgldk - TriplyDB

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

http://www.wikidata.org/entity/Q37903003

about

Pharmacoepidemiology resources in Ireland-an introduction to pharmacy claims data.Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.

P2860

Q38618923-EE917A9A-6C5A-4425-8911-CBCE8D0118D7 Q47653552-9CD23034-D99A-411E-BEC1-A773755910B0

P2860

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

http://www.wikidata.org/entity/Q37903003

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@en

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@nl

type

label

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@en

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@nl

prefLabel

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@en

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@nl

P1433

Q37903003-5DB236E9-45A3-401B-8BEE-C35E39B6BFCA

P1476

Q37903003-D9B5BAF7-B8A8-4B0F-8219-F7AC46060EA9

P2093

Q37903003-2315D4BF-9C5C-4422-A20E-D1D2EBF84851

Q37903003-3AA5B307-1088-48D4-A8FA-118DD0077573

Q37903003-6BBADAB8-5E52-4F1C-B2A5-5A896CFEE47C

Q37903003-EE34CA35-9D17-4BDF-972D-DA6A18D52660

P2860

Q37903003-0716FC42-B17A-47FE-ACC8-24FD53A34228

Q37903003-11CE3C9C-79DC-4CB0-A8AA-B7285B0A3FE8

Q37903003-222ECEE1-EA45-47D7-BF2A-0FD2F32597DA

Q37903003-28E26470-C9D2-4A58-A829-6B8F88FC408F

Q37903003-30945439-2D1D-461F-8297-2E7F36DAE67B

Q37903003-3A0ABCEF-6BFB-4986-99D8-3EC45F6D3360

Q37903003-4B4FDDA0-9F5C-45D2-809B-40B7B714D229

Q37903003-4FD8E7FC-F0B7-4943-94C5-595826E0E661

Q37903003-5087F830-1D35-44E0-A83D-D3434281BBA3

Q37903003-54DA5AFC-0D22-4262-8484-1AAC1CB2334A

P304

Q37903003-11127B3F-83BF-4D5F-8DCE-AC88277C0839

P31

Q37903003-77130A66-56F1-4D7E-8118-15C762126654

P356

Q37903003-6C3D749B-9DED-4B91-8ABA-BCA876F4A998

P433

Q37903003-563E722C-FB0E-495E-997E-E5E37C071C3D

P478

Q37903003-EC1E4002-B519-4C4D-AB65-7C0AB1D14954

P577

Q37903003-2030B763-DBF8-4018-9DDD-0542C288850F

P698

Q37903003-46E6FDE1-82AD-49C2-B13E-8094A0518EA3

P356

P1433

Pharmacoepidemiology and Drug Safety

P1476

Irish Medicines Board safety warnings: do they affect prescribing rates in primary care?

@en

P2093

K Bennett

http://www.w3.org/2001/XMLSchema#string

N L Zaharan

http://www.w3.org/2001/XMLSchema#string

S Kraus

http://www.w3.org/2001/XMLSchema#string

S Musleh

http://www.w3.org/2001/XMLSchema#string

P2860

Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists: the tortoise and the hare revisited

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Why don't physicians follow clinical practice guidelines? A framework for improvement

Antibiotic use in ambulatory care in Europe (ESAC data 1997-2002): trends, regional differences and seasonal fluctuations.

Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.

Optimization of antiplatelet/antithrombotic therapy for secondary stroke prevention.

New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra)

Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases.

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.

P304

979-986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PDS.2199

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21774032

http://www.w3.org/2001/XMLSchema#string